KENNESAW, Ga., Aug. 7, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has closed a clinical trial involving its EpiFix® dehydrated human amniotic membrane allograft for the treatment of diabetic neurovascular foot ulcers.
This prospective trial design initially targeted 80 patients. Those patients selected for the randomized, controlled trial were treated with either a well accepted standard of care program for diabetic foot ulcers or standard of care plus an application of EpiFix®, a MiMedx allograft processed from human amniotic membrane.
Results from the Institutional Review Board ("IRB") approved randomized controlled trial indicated a statistically significant improvement in the healing of wounds treated with EpiFix® compared with patients receiving the standard of care treatment alone. The trial results indicated a significant healing rate, with 92% of the patients in the EpiFix® study arm healed completely at six weeks, contrasted with only 8% of the standard of care control arm patients healed in the same time frame. After reviewing and validating the results with two additional independent wound researchers, the principal investigator recommended termination of the trial earlier than initially expected, and the IRB and MiMedx accepted the early closure of the study. These findings are expected to be submitted for peer reviewed journal publication within the month.
"The intent of the trial was to generate clinical data in treating diabetic foot ulcers with EpiFix®, which has shown strong clinical and cost effectiveness. EpiFix® currently has product specific coding from CMS to permit billing for Medicare patients. This newly generated data will further support continued and expanded Medicare coverage of EpiFix®," said Bill Taylor, President and COO of MiMedx Group.MiMedx continues characterization of the EpiFix® allografts with several scientific and clinical studies, including frequency of application and cost effectiveness in various wound types. In addition, the Company has similar active clinical studies for its AmnioFix® allograft, which is used for surgical procedures, and its AmnioFix® Injectable, which is used for the enhancement of soft tissue healing.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts